- Oral Abstract Session - Pediatric Oncology
- Poster Discussion Session - Pediatric Oncology
Oral Abstract Session - Pediatric Oncology
Abstract 10000: Updated safety and efficacy data from an open-label, phase 1/2 study of frontline brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) in pediatric patients with advanced-stage classical Hodgkin lymphoma (cHL).
Presenter: Anna Rachel Keating Franklin
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10000
---------------------------------------------------------------------------------------------------------------------------
Abstract 10001: Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): Results from the phase 2 DELPHINUS study.
Presenter: Laura E. Hogan
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10001
---------------------------------------------------------------------------------------------------------------------------
Abstract: 10002: BEACON-Immuno: Results of the dinutuximab beta (dB) randomization of the BEACON-Neuroblastoma phase 2 trial—A European Innovative Therapies for Children with Cancer (ITCC–International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial.
Presenter: Juliet Gray
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10002
---------------------------------------------------------------------------------------------------------------------------
Abstract 10003: A pilot induction regimen incorporating dinutuximab and sargramostim for the treatment of newly diagnosed high-risk neuroblastoma: A report from the Children's Oncology Group.
Presenter: Sara Michele Federico
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10003
---------------------------------------------------------------------------------------------------------------------------
Abstract: 10004: Poverty, race, ethnicity, and survival among U.S. children with non-metastatic osteosarcoma treated on EURAMOS-1: A report from the Children’s Oncology Group.
Presenter: Lenka Anne Skaidrite Ilcisin
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10004
---------------------------------------------------------------------------------------------------------------------------
Abstract 10005: Racial, ethnic, and socioeconomic survival disparities among children with high-risk neuroblastoma treated on upfront Children’s Oncology Group clinical trials.
Presenter: Puja J Umaretiya
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10005
---------------------------------------------------------------------------------------------------------------------------
Abstract 10006: Securing access to innovative anticancer therapies for children, adolescents, and young adults outside clinical trials: The SACHA study of the French Society of Pediatric Oncology (SFCE).
Presenter: Pablo Berlanga
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10006
---------------------------------------------------------------------------------------------------------------------------
Abstract 10007: Late mortality and morbidity among adult survivors of childhood glioma treated over three decades: A report from the Childhood Cancer Survivor Study.
Presenter: Peter de Blank
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10007
---------------------------------------------------------------------------------------------------------------------------
Abstract: 10008: Joint effects of general population polygenic risk scores (PRS) and radiation treatment on subsequent neoplasm risk among childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS).
Presenter: Todd M. Gibson
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10008
---------------------------------------------------------------------------------------------------------------------------
To watch the Presentation and Discussion of this Oral Abstract Session you need an ASCO Annual Meeting registration
----------------------------------------------------------------------------------------------------------------------------
POSTER SESSION
Pediatric Oncology
https://meetings.asco.org/2022-asco-annual-meeting/14401?presentation=206937#206937
Poster Discussion Session - Pediatric Oncology
Abstract 10009: Tazemetostat in patients with tumors with alterations in EZH2 or the SWI/SNF complex: Results from NCI-COG Pediatric MATCH trial Arm C (APEC1621C).
Presenter: Susan N. Chi | Poster: 224
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10009
------------------------------------------------------------------------------------------------------------------------
Abstract 10010: Matched external control analysis of event-free survival (EFS) in patients with high-risk neuroblastoma (HRNB) receiving eflornithine (DFMO) maintenance.
Presenter: Javier E. Oesterheld | Poster: 225
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10010
------------------------------------------------------------------------------------------------------------------------
Abstract 10011: STRIVE-02: A first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed/refractory solid tumors.
Presenter: Navin R. Pinto | Poster: 226
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10011
------------------------------------------------------------------------------------------------------------------------
Abstract 10012: Pediatric EBV-negative monomorphic post–solid organ transplant lymphoproliferative disorders [EBV(-)M-PTLD]: Characteristics, treatment, and outcome from 11 pediatric academic centers.
Presenter: Zeinab A.M. Afify | Poster: 227
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10012
------------------------------------------------------------------------------------------------------------------------
Abstract: 10013: Survival of patients with neuroblastoma before versus after reduction of therapy due to the change in age cut-off from 12 to 18 months in Children’s Oncology Group (COG) risk stratification.
Presenter: Wendy B. London | Poster: 228
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10013
------------------------------------------------------------------------------------------------------------------------
Abstract 10014: Modifiable risk factors for late mortality among five-year survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.
Presenter: Stephanie B Dixon | Poster: 229
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10014
------------------------------------------------------------------------------------------------------------------------
Abstract 10015: Benefits, harms, and burden of colorectal cancer screening among childhood cancer survivors previously treated with abdominal-pelvic radiation.
Presenter: Jennifer M Yeh | Poster: 230
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10015
------------------------------------------------------------------------------------------------------------------------
Abstract 10016: Outcomes of Hispanic and non-Hispanic white pediatric and young adult patients with B-cell acute lymphoblastic leukemia after commercial tisagenlecleucel.
Presenter: Panayiotis Vandris | Poster: 231
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10016
------------------------------------------------------------------------------------------------------------------------
Abstract 10017: Racial and ethnic differences in presentation and clinical outcomes for pediatric rhabdomyosarcoma (RMS).
Presenter: Princess Ekpo | Poster: 232
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10017
------------------------------------------------------------------------------------------------------------------------
Abstract 10018: Barriers to effective childhood cancer control in Kenya (BECK) study, 2019-2020: A mixed methods study in a national tertiary facility and 10 regional cancer treatment centers.
Presenter: Valerian Mwenda | Poster: 233
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10018
------------------------------------------------------------------------------------------------------------------------
Abstract 10019: Identifying trends for high symptom burden across the care continuum in adolescents and young adults (AYA) with hematologic malignancies.
Presenter: Sarah Elizabeth Monick | Poster: 234
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10019
------------------------------------------------------------------------------------------------------------------------
Abstract 10020: Neuropathy and neurocognitive impairment in long-term survivors of pediatric cancer treated without central nervous system (CNS) directed therapy.
Presenter: AnnaLynn Williams | Poster: 235
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.10020
------------------------------------------------------------------------------------------------------------------------
To watch the Presentation and Discussion of this Poster Discussion Session you need an ASCO Annual Meeting registration